Clinical Characteristics and Outcomes in NSCLC Patients Associated with Very High PD-L1 Expression

被引：0
|
作者：
Mcloughlin, E. [1 ]
Hanson, L. [2 ]
Moore, M. [3 ]
Horton, B. [4 ]
Gentzler, R. [1 ]
Hall, R. [1 ]
机构：
[1] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[2] Univ Virginia, Med, Charlottesville, AL USA
[3] Univ Virginia, Sch Med, Charlottesville, AL USA
[4] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Non-Small Cell Lung Cancer; metastatic;
D O I：
10.1016/j.jtho.2019.08.1395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-52
引用
收藏
页码：S659 / S660
页数：2
相关论文
共 50 条
  • [31] Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
    Kucharczyk, T.
    Grenda, A.
    Krawczyk, P.
    Nicos, M.
    Jarosz, B.
    Szumilo, J.
    Reszka, K.
    Trojanowski, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S732 - S732
  • [32] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [33] PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Bai, Yuchen
    Chen, Xiaoxia
    Hou, Likun
    Qian, Jun
    Jiang, Tao
    Zhou, Caicun
    Ciebiada, Maciej
    CANCER BIOLOGY & MEDICINE, 2018, 15 (04) : 434 - +
  • [34] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
    Piedra, A.
    Barba Joaquin, A.
    Mosquera Martinez, J.
    Fernandez Bruno, M.
    Cordeiro Gonzalez, P.
    Sullivan, I. G.
    Riudavets Melia, M.
    Aguado Sorolla, M.
    Gallardo Melo, P.
    Martin Cullell, B.
    Gavira, J.
    Tapia, J. C.
    Romano, A.
    Bosma, F.
    Sanchez Del Rio, S.
    Sanz Beltran, J.
    Molina Perez, M. A.
    Serra Lopez, J.
    Garcia Campelo, M. R.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053
  • [35] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Chen, Justin A.
    Riess, Jonathan W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (07)
  • [36] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Justin A. Chen
    Jonathan W. Riess
    Current Treatment Options in Oncology, 2020, 21
  • [37] Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients
    Elliot Naidus
    Jerome Bouquet
    David Y. Oh
    Timothy J. Looney
    Hai Yang
    Lawrence Fong
    Nathan E. Standifer
    Li Zhang
    Cancer Immunology, Immunotherapy, 2021, 70 : 2095 - 2102
  • [38] Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients
    Naidus, Elliot
    Bouquet, Jerome
    Oh, David Y.
    Looney, Timothy J.
    Yang, Hai
    Fong, Lawrence
    Standifer, Nathan E.
    Zhang, Li
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 2095 - 2102
  • [39] Clinical characteristics and PD-L1 expression of pulmonary sarcomatoid carcinoma
    Lee, Sung Yong
    Shim, Jae Kyeom
    Oh, Jee Youn
    Min, Kyung Hoon
    Hur, Gyu Young
    Shim, Jae Jeong
    Kang, Kyung Ho
    Shin, Bong Kyung
    Lee, Young Seok
    CANCER RESEARCH, 2017, 77
  • [40] Biological and clinical relevance of PD-L1 expression in tumor and inflammatory cells in NSCLC
    Bais, Carlos
    Morehouse, Chris
    Higgs, Brandon W.
    Marlon, Rebelatto
    Steele, Keith
    Jin, Xiaoping
    Shi, Li
    Korolevich, Susana
    Gupta, Ashok
    Ranade, Koustubh
    CANCER RESEARCH, 2017, 77
12345